(bortezomib plus lenalidomide/thalidomide) vs (bortezomib or lenalidomide/thalidomide)-containing regimens as induction Therapy in newly diagnosed multiple myeloma:a meta-analysis of randomized controlled trials

摘要：

　　Aim To perform a meta-analysis of the efficacy and safety of (bortezomib plus lenalidomide/thalidomide) vs (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma.Methods We searched electronic and printed sources for relevant articles published.Inclusion criteria was as follows:randomized controlled trials (RCT) of (bortezomib plus lenalidomide/thalidomide) vs (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma.Two reviewers independently assessed potentially eligible studies and extracted relevant data.Results We retrieved 5 RCT studies including a total of 1200 patients.

作者: Anyou Wang Qiaohong Duan Xin Liu Kaiyang Ding Yongsheng Han Weibo Zhu Xiaoyan Cai Jingsheng Wu Zimin Sun

作者单位: Department of Hematology, Anhui Medical University Affiliated Anhui Provincial Hospital, Hefei, Anhui, China, 230001

会议类型: 国内会议

会议名称: 安徽省第十二次血液学学术会议暨中国脐血移植协作组第五次会议

会议地点: 合肥

会议语种:英文

页码: 169-169

在线出版日期: 2012-08-24（万方平台首次上网日期，不代表论文的发表时间）